Data show control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123 These results support clinical development of CD123-NKCE; A Phase 1/2 clinical trial by...

Sanofi gains exclusive license to Innate’s B7H3 ANKET TM program and options for two additional targets; Upon candidate selection, Sanofi will be responsible for all development, manufacturing and...

Lacutamab demonstrated encouraging efficacy and a favorable safety profile in heavily pretreated, post-mogamulizumab patients with advanced Sézary syndrome In addition, Innate’s ANKET TM (Antibody...

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation...

Phase 1 data for IPH5201, a CD39-blocking monoclonal antibody, as monotherapy or in combination with durvalumab, in advanced solid tumors to be presented by partner AstraZeneca Preclinical data...

Preliminary data from ongoing Phase 2 TELLOMAK trial of lacutamab demonstrated clinical activity in mycosis fungoides, presented at EORTC-CLTG annual meeting Preliminary Sezary syndrome lacutamab...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announced that the Company will hold a conference call on Monday, November 14, 2022, at 2 p.m. CET / 8 a.m...

Innate will share preliminary results of the cohort evaluating lacutamab in Sezary syndrome patients post-mogamulizumab from the ongoing TELLOMAK Phase 2 trial Chief Scientific Officer, Eric Vivier...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its senior management team are scheduled to participate in the following upcoming...